BlackRock Portfolio Management LLC filed a Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 1,645,489 shares of LENZ Therapeutics, Inc. common stock, representing 5.2% of the class, as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock Portfolio Management LLC reported beneficial ownership of 1,645,489 shares of LENZ Therapeutics common stock.
  • Percent of class: The reported position equals 5.2% of the outstanding common shares.
  • Sole voting power: The filing reports sole voting power over 1,395,487 shares, with zero shared voting power.
  • Sole dispositive power: The filing reports sole dispositive power over 1,645,489 shares, with zero shared dispositive power.
  • Event date: The date of the event requiring the filing was September 30, 2026.
  • Ordinary course certification: The filer certified that the securities were acquired and are held in the ordinary course of business and not to influence control of the issuer.

BlackRock Portfolio Management's Reported Position in LENZ Therapeutics

According to the Schedule 13G filed on October 27, 2026, BlackRock Portfolio Management LLC, organized in Delaware and headquartered at 50 Hudson Yards, New York, NY 10001, disclosed beneficial ownership of 1,645,489 shares of common stock (CUSIP 52635N103) of LENZ Therapeutics, Inc. (NASDAQ:LENZ). The filing was signed by Spencer Fleming, Managing Director, on behalf of BlackRock Portfolio Management LLC. The triggering event date is listed as September 30, 2026.

The filing reports that sole voting power covers 1,395,487 shares, while sole dispositive power covers the full 1,645,489 shares. Shared voting and shared dispositive power are each reported as zero. The filer is classified as type "HC" (holding company) on the cover page. Per the filing, the Schedule 13G "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates" and does not include securities beneficially owned by other business units whose beneficial ownership is disaggregated in accordance with SEC Release No. 34-39538.

Regarding dividends and proceeds, the filing states that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of LENZ THERAPEUTICS, INC." and that no single person's interest exceeds five percent of total outstanding common shares. The filing references Exhibit 99 for identification of relevant subsidiaries under Item 7.

What Was Disclosed

BlackRock Portfolio Management LLC filed a Schedule 13G disclosing 1,645,489 shares, or 5.2%, of LENZ Therapeutics common stock as of September 30, 2026, with sole voting power over 1,395,487 shares and sole dispositive power over the full reported position.